Catalent has developed a relative potency bioassay using quantitative polymerase chain reaction (qPCR) to assess relative transcription activity in cells treated with ligands or transgenic vectors. The assay platform can be used to qualify a repeatable, accurate, linear, and specific bioassay for assessing relative potency for CGTs, mRNA- and other nucleic acid-based therapies.

Catalent Biologics provides characterization and GMP support for a full spectrum of biologics including advanced modalities, such as cell and gene therapies, mRNA, and antibody-drug conjugates (ADCs). Our comprehensive, standalone analytical services for ADCs are conducted by our in-house experts and tailored to meet your needs, regardless of scope or phase.

During this webinar, Catalent experts will discuss challenges associated with charged variants of biotherapeutic products, including monoclonal antibodies and fusion proteins.

Summary: Supply chains have come under intense pressure, and companies have had to adapt to this “new normal” to avoid delays. During this Q&A, Catalent discusses....

Summary: Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.

Summary: Experts discuss formulation development and purification strategies to increase throughput, reduce operating costs and decrease...

Summary: During this presentation, experts will discuss the latest challenges in biophysical characterization and will present solutions to overcome these challenges.

Summary: This will be Endpoints’ 2021 look at 11 of the most important up-and-coming private biotechs in the business, independently selected by company founder and editor John Carroll.

Summary: This webinar summarizes the current bioanalytical landscape and its challenges, and discusses strategies to overcome them.

Summary: In this webinar, leaders in the field discuss new vaccines and drugs that have resulted from COVID and key learnings to prepare for the next pandemic.